Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3

Sorbye, 2013, Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study, Ann Oncol, 24, 152, 10.1093/annonc/mds276 Velayoudom-Cephise, 2013, Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocr Relat Canc, 20, 649, 10.1530/ERC-13-0027 Heetfeld, 2015, Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms, Endocr Relat Canc, 22, 657, 10.1530/ERC-15-0119 Basturk, 2015, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms, Am J Surg Pathol, 39, 683, 10.1097/PAS.0000000000000408 Tang, 2016, Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas, Clin Canc Res, 22, 1011, 10.1158/1078-0432.CCR-15-0548 Crippa, 2016, Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters, Surgery, 159, 862, 10.1016/j.surg.2015.09.012 2019 Garcia-Carbonero, 2017, ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy, Neuroendocrinology, 105, 281, 10.1159/000473892 Garcia-Carbonero, 2016, ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas, Neuroendocrinology, 103, 186, 10.1159/000443172 Fischer, 2014, Outcome of surgery for pancreatic neuroendocrine neoplasms, Br J Surg, 101, 1405, 10.1002/bjs.9603 Yang, 2015, Survival analyses for patients with surgically resected pancreatic neuroendocrine tumors by World Health organization 2010 grading classifications and American joint committee on cancer 2010 staging systems, Medicine (Baltim), 94, 10.1097/MD.0000000000002156 Shen, 2016, Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience, BMC Gastroenterol, 16, 111, 10.1186/s12876-016-0505-5 Partelli, 2015, Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases, Neuroendocrinology, 102, 68, 10.1159/000431379 Yoshida, 2019, Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately, Ann Surg Oncol, 26, 1385, 10.1245/s10434-019-07252-8 Yang, 2019, Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: a comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems, Eur J Surg Oncol, 45, 1054, 10.1016/j.ejso.2019.01.010 Partelli, 2018, The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms, Eur J Surg Oncol, 44, 778, 10.1016/j.ejso.2018.03.005 Yamaguchi, 2014, Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system, Canc Sci, 105, 1176, 10.1111/cas.12473 Iwasa, 2010, Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas, Jpn J Clin Oncol, 40, 313, 10.1093/jjco/hyp173 Patta, 2011, First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases, Anticancer Res, 31, 975 Okita, 2011, Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma, Gastric Cancer, 14, 161, 10.1007/s10120-011-0025-5 Lu, 2013, Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas, Med Oncol, 30, 664, 10.1007/s12032-013-0664-y Okuma, 2014, Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus, Anticancer Res, 34, 5037 Rogowski, 2019, Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma, Retrosp. Anal Endokrynol Pol, 70, 313, 10.5603/EP.a2019.0010 Pellat, 2018, Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms, Neuroendocrinology, 107, 24, 10.1159/000487237 Panzuto, 2017, Everolimus in pancreatic neuroendocrine carcinomas G3, Pancreas, 46, 302, 10.1097/MPA.0000000000000762 Zhang, 2019, Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients, J Nucl Med, 60, 377, 10.2967/jnumed.118.215848 Carlsen, 2019, Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study, Endocr Relat Canc, 26, 227, 10.1530/ERC-18-0424 Collot, 2018, Bevacizumab-based chemotherapy for poorly-differentiated neuroendocrine tumors, Anticancer Res, 38, 5963, 10.21873/anticanres.12943 Klöppel, 2017, vol. 10 Galleberg, 2017, Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas, Eur J Surg Oncol, 43, 1682, 10.1016/j.ejso.2017.04.010 Deng, 2018, The role of surgery in treating resectable limited disease of esophageal neuroendocrine carcinoma, World J Surg, 42, 2428, 10.1007/s00268-018-4475-3 Maire, 2009, Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors?, Surgery, 145, 69, 10.1016/j.surg.2008.08.007 Ramella Munhoz R1, 2013, Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas, Rare Tumors, 5, e39, 10.4081/rt.2013.e39